advertisement
Abstract #6462 Published in IGR 3-2
Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma
Konstas AGP; Stewart WC; Topouzis F; Tersis I; Holmes KT; Stangos NTAmerican Journal of Ophthalmology 2001; 131: 729-733
PURPOSE: To evaluate the efficacy and safety of brimonidine 0.2% two or three times daily versus timolol maleate 0.5% solution twice daily. METHODS: Patients with primary open-angle glaucoma (POAG) were randomized by Latin square technique to one of the three treatment sequences in this crossover, prospective, double-masked trial. Each treatment period consisted of six weeks of chronic dosing followed by a diurnal curve for the intraocular pressure (IOP) measured at 08.00, 10.00, 16.00, 18.00, 20.00, 22.00, and 24.00 hours. IOP was measured by applanation tonometry. RESULTS: Thirty patients completed this trial. The average diurnal IOPs in the trial were measured for timolol maleate (17.7 ± 2.7 mmHg), brimonidine given three times daily (18.0 ± 2.2 mmHg), and brimonidine given twice daily (19.2 ± 2.4 mmHg). There was a statistical difference between groups (p < 0.005). When groups were compared by pairs, three times daily dosing with brimonidine and timolol maleate both reduced the pressure more than twice daily brimonidine at every time point past 10.00 hours, and for the diurnal curve (p < 0.05). In contrast, three times daily brimonidine and timolol maleate were statistically similar for the diurnal pressure, at each time point, except that timolol maleate decreased the pressure more at 16.00 hours (p = 0.042). Safety was similar between groups. CONCLUSIONS: This study demonstrated that both timolol maleate twice daily and brimonidine three times daily provide a similar IOP reduction to each other. Timolol maleate twice daily and brimonidine three times daily provide a greater decrease in pressure in the late afternoon and nighttime hours, compared with brimonidine twice daily.
Dr W.C. Stewart, Pharmaceutical Research Corporation, 1639 Tatum Street, Charleston, SC 29412-2646, USA
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
